Determination of Regulatory Review Period for Purposes of Patent Extension; BLUJEPA

Summary

The FDA has determined the regulatory review period for BLUJEPA, a human drug product, and is publishing the notice as required by law. The review period is due to a patent extension application submitted to the USPTO.